Archive for the ‘Treatment’ Category

Evaluation of Disulfiram Drug Combinations & Identification of Other More Effective Combinations against Stationary Phase Borrelia burgdorferi

https://www.mdpi.com/2079-6382/9/9/542

Evaluation of Disulfiram Drug Combinations and Identification of Other More Effective Combinations against Stationary Phase Borrelia burgdorferi

by Hector S. Alvarez-Manzo, Yumin Zhang, Wanliang Shi and Ying Zhang 

Antibiotics2020, 9(9), 542; https://doi.org/10.3390/antibiotics9090542 (registering DOI)Received: 7 August 2020 / Revised: 21 August 2020 / Accepted: 25 August 2020 / Published: 26 August 2020View Full-TextDownload PDFBrowse Figures

Abstract

Lyme disease, caused by Borrelia burgdorferi, is the most common vector-borne disease in USA, and 10–20% of patients will develop persistent symptoms despite treatment (“post-treatment Lyme disease syndrome”). B. burgdorferi persisters, which are not killed by the current antibiotics for Lyme disease, are considered one possible cause. Disulfiram has shown to be active against B. burgdorferi, but its activity against persistent forms is not well characterized. We assessed disulfiram as single drug and in combinations against stationary-phase B. burgdorferi culture enriched with persisters.

  • Disulfiram was not very effective in the drug exposure experiment (survival rate (SR) 46.3%) or in combinations.
  • Clarithromycin (SR 41.1%) and nitroxoline (SR 37.5%) were equally effective when compared to the current Lyme antibiotic cefuroxime (SR 36.8%) and more active than disulfiram.
  • Cefuroxime + clarithromycin (SR 25.9%) and cefuroxime + nitroxoline (SR 27.5%) were significantly more active than cefuroxime + disulfiram (SR 41.7%).
  • When replacing disulfiram with clarithromycin or nitroxoline in three-drug combinations, bacterial viability decreased significantly and subculture studies showed that combinations with these two drugs (cefuroxime + clarithromycin/nitroxoline + furazolidone/nitazoxanide) inhibited the regrowth, while disulfiram combinations did not (cefuroxime + disulfiram + furazolidone/nitazoxanide).

Thus, clarithromycin and nitroxoline should be further assessed to determine their role as potential treatment alternatives in the future.View Full-Text

_______________________

For more:

https://madisonarealymesupportgroup.com/2020/12/07/repurposing-disulfiram-in-the-treatment-of-lyme-disease-and-babesiosis-retrospective-review-of-first-3-years-experience-in-one-medical-practice/

https://madisonarealymesupportgroup.com/2020/11/30/patients-can-respond-very-differently-to-disulfiram-be-cautious/

https://madisonarealymesupportgroup.com/2020/10/01/study-shows-dsm-works-for-lyme-reduces-inflammatory-markers-antibody-titers/

https://madisonarealymesupportgroup.com/2019/11/19/if-disulfiram-is-the-cure-for-lyme-disease-should-it-be-prescribed-to-all-lyme-disease-patients/

https://madisonarealymesupportgroup.com/2020/06/26/new-treatments-for-lyme-disease-on-the-horizon/

https://madisonarealymesupportgroup.com/2016/02/13/lyme-disease-treatment/

Category:

Lyme, research, Treatment

SOT Treatment For Lyme Disease

SOT was created for those with previously untreatable genetic conditions.  In my opinion, Lyme disease is not a genetic condition, it’s an infection(s) and depending upon your exact case, is only one of many potential infections that can be bacterial, fungal, viral, and/or parasitic.  This is my main problem with SOT besides the fact it is a gene-silencing technique that raises questions about long-term effects as well as the fact Bb changes its outer surface protein, is stealthy, and very probably a bioweaponized pathogen(s) created in a lab to be more persistent and transmissible, and to evade the immune system and treatment.

https://www.treatlyme.net/guide/sot-lyme-treatment

SOT for Lyme Image from Marty Ross MD
 
By Marty Ross MD

Supportive Oligonucleotide Therapy (SOT) Background

Supportive Oligonucelotide Therapy (SOT) is a new treatment for Lyme disease. SOT is also called Antisense Oligonucelotide Therapy (ASOT) which is the term used in medical research papers. SOT uses laboratory derived nucleic acids (genetic code) that blocks production of disease causing proteins or even gene expression. These pieces of genetic code are called oligonucleotides. You can think of oligonucleotides as a genetic message.

For example, in Duchenne Muscular Dystrophy (DMD), SOT provides oligonucleotides that direct the correct production of a protein called dystrophin. People with muscular dystrophy are born with DNA that provides the wrong genetic message for dystrophin. SOT correction to the DNA message leads to production of dystrophin. This prevents the muscle damage seen in DMD.

In Lyme disease, a currently available type of SOT produced by RGCC in Greece uses oligonucleotides intended to stop germ growth and replication. Unlike the SOT therapy for Duchenne muscular dystrophy, the Lyme SOT is not a US Food and Drug Administration (FDA) approved drug. To be approved by the FDA, a therapy must have scientific evidence of safety and effectiveness.  (See link for article)

______________________

**Comment**

Dr. Ross is unsure if SOT for Lyme/MSIDS works, and some of his patients using it before seeing him experienced little to no effects, but some of his colleagues state some patients have experienced improvement.  He also reminds readers that there is a placebo effect of 35% on average in clinical trials for drugs.

Also, please read this article on SOT Therapy side effects.

Common side effects: injection site reactions, flu-like symptoms, headaches and fatigue, changes in liver function.

Serious but supposedly rare side effects: thrombocytopenia, changes in kidney function, allergic reactions, neurological effects, potential impact on fertility and pregnancy.

For more on SOT:

For more on the RGCC test:

 

 

 

 

Category:

Lyme, Treatment

Symptomatic High-Grade AV Block & Phase 4 Right Bundle Branch Block – A Previously Unreported Manifestation in Lyme Carditis

https://www.heartrhythmcasereports.com/article/S2214-0271(20)30263-3/fulltext#secsectitle0020

Phase 4 Block of the Right Bundle Branch Suggesting His-Purkinje System Involvement in Lyme Carditis

Open AccessPublished: December 01, 2020DOI:https://doi.org/10.1016/j.hrcr.2020.11.017
We describe an adolescent with symptomatic high-grade AV block and evidence of phase 4 right bundle branch block, a previously unreported manifestation of infra-nodal conduction system involvement in LC.

A previously healthy 14-year-old boy presented via emergency medical services in mid-summer because of syncope (fainting).

Interesting findings:

  • Patient frequently hunts and fishes in wooded, Lyme-endemic region 
  • Didn’t remember tick bites or EM rash
  • Two weeks prior to ER visit patient had a runny nose, cough, abdominal pain, followed by headache and nausea.
  • In the ER he had bradycardia, altered mental status, headache, and vomiting.
  • Initial ECG showed complete heart block
  • He was given 2,000mg of IV Ceftriaxone every 24 hours
  • Testing supported clinical suspicion of Lyme
  • He was given a temporary pace-maker which was removed after 5 days of IV antibiotics and he was switched to oral doxycycline to complete a total of 21 days of antibiotics
  • After being monitored in hospital for 7 days, he was discharged with an auto-detecting wireless monitor until a follow-up appointment and stress test
  • Follow-up appointment patient was well with normal ECG

_____________________

**Comment*

Case study states: 

Significant AV block due to LC occurs in about 1% of LD cases.

I believe this statistic is premature considering many do not test positive and therefore are undiagnosed. I’ve posted numerous articles where patients are sent packing even when they present with positive test results three times in a row! We will never know how many patients with AV block have an underlying tick-borne illness due to abysmal testing and the lack of training and experience of most doctors with tick-borne illness.

And then there’s that nagging concern about long-term effects and if 21 days of antibiotics were enough for his patient. It often isn’t.

Please see:

https://madisonarealymesupportgroup.com/2020/11/25/what-makes-a-doctor-lyme-literate/

Category:

Heart Issues, Lyme, research, Testing, Treatment

Ozone for Newbies Webinar Tonight

Webinar: Ozone for Newbies

Click below to sign up for a free webinar on Thursday (12/18) 
at 8PM Central Time. 

What is something you have always wanted to know about ozone?

My goal for this webinar is to give you a place for asking any ozone therapy question you have and to teach you the basics of ozone therapy.

You will be able to interact and ask questions during this live webinar!

The webinar starts this Thursday (12/18) at 8PM Central.

Click the link to sign up and get reminders as it gets close.

Click here to register 
https://event.webinarjam.com/register/21/k3851al

Looking forward to learning with you, 

Jason DeLeon – Professional Ozonaut
P.S.  If you can’t make it, you can still sign up and get the video afterward!  Click here to register

Category:

Activism, Treatment

Lyme Disease is a Small Vessel Disease: Dr. Klemann

http://

Dr. Wolfgang Klemann – Lyme disease is a small vessel disease

July 2, 2016

In this short video, Dr. Klemann describes how quickly borrelia leaves the blood (within hours) to infect small vessels. This, along with biofilm and round-body forms are reasons why blood (serology) testing will not work.

He describes how borrelia has an enzyme to break down collagen tissue, form colonies and a protective slime layer.  He states that antibiotics target the outer layer of the biofilm, but not the inner layer and that longer treatment is imperative for effectiveness.

As it stands, the CDC/IDSA only acknowledges the acute stage of Lyme disease, with short treatment.  They ignore those with chronic/persistent illness and simply state it doesn’t exist or is a figment of your imagination.  https://madisonarealymesupportgroup.com/2020/12/10/ten-things-you-should-know-about-the-new-idsa-lyme-guidelines/

Do not mess around with these doctors.

Get to an ILADS trained Lyme literate doctor who understands treatment nuances and that treatment often surpasses the accepted narrative of 21 days of doxycycline.  Please see:  https://madisonarealymesupportgroup.com/2020/11/25/what-makes-a-doctor-lyme-literate/

This is not to say you won’t have to perhaps see a regular doctor for specific issues, as Lyme/MSIDS affects so many organs; however, the main doctor in charge of treating tick-borne illness should be Lyme literate.

For more:  https://madisonarealymesupportgroup.com/2016/02/13/lyme-disease-treatment/

 

 

Category:

Lyme, Treatment